UnitedHealthcare's documents for Wegovy
- Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only (policy 2026 P 1445-4)
The plan's own lines
Quoted from the plan's document, word for word.
For Cardiovascular Risk Reduction
Previous treatment history
- “For patients with history of ischemic or hemorrhagic stroke” (Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only)
- “For patients with history of symptomatic PAD” (Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only)
For MASH
Authorization review
- “Documentation of positive clinical response to Wegovy injection” (Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only)
- “Patient has not progressed to cirrhosis” (Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only)
What this medicine is used for
“to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition”
From the FDA label for Wegovy, revised April 23, 2024. The label is shown in English as published. DailyMed. Your doctor decides what it is used for in your case.
Common questions
Does UnitedHealthcare require prior authorization for Wegovy?
UnitedHealthcare's documents for Wegovy are linked on this page; the plan's document holds the details.
How do I see the policy for my own plan and state?
Open the free KAIS guide, pick your plan, your type of plan, your state and your medicine, and it shows the policy your plan publishes, with the link to the plan's own document.
Not medical advice and not a decision on your claim. Your doctor and your plan decide.